VOLITIONRX LTD
VNRXNYSE AMERICANTrading Snapshot
- Day Range
- $0.16 โ $0.17
- 52-Week Range
- $0.16 โ $7.80
- Volume (shares)
- 1,200,851
- Avg Volume (shares)
- โ
- Shares Outstanding
- 12.0M
- Next Earnings
- 2027-03-30
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $2M
- P/E Ratio
- -0.1
- P/S Ratio
- 0.6x
- EPS (TTM)
- $-1.27
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +23.5%
VOLITIONRX LTD
VNRXAbout VOLITIONRX LTD
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

VolitionRx Highlights a Transformational Year: Clinical Validation, Commercial Partnerships, and Potential Upcoming Milestones
Peer-reviewed validation in sepsis, >95% early-stage cancer detection in a blinded cohort, a government-funded sepsis program in France, licensing discussions with more than a dozen diagnostic companies worldwide, an exp

Volition Expands Contract with Fujifilm to Include the Nu.Qยฎ Vet Test for Cats
Expansion extends potential use of Nu.Qยฎ technology to Japan's almost nine million cats Volition expects Nu.Qยฎ Vet Feline Test to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer H

VolitionRx Limited (VNRX) Q3 2026 Earnings Call Transcript
VolitionRx Limited (VNRX) Q3 2026 Earnings Call Transcript

VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Friday, November 13 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.

VolitionRx Limited Schedules Third Quarter 2026 Earnings Conference Call and Business Update
Conference call to take place on Friday, November 13 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.

VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide
HENDERSON, Nev., Oct. 27, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has executed a non-binding Letter of Intent ("LOI") with